AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25287762
Drug: Orodispersible L-carnosine
RxNorm normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orodispersible L-carnosine (500 mg OD)
Trial: 21194693
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lycopene daily for 8 weeks
Trial: 21194693
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg lycopene daily for 8 weeks
Trial: 13678475
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate (RIS) 5 mg daily
Trial: 6426377
Drug: Self-care medication
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-care medication program
Trial: 30767274
Drug: Eculizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median])
Trial: 28163732
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy and dry needling (DN)
Trial: 14996106
Drug: Tetracaine gel
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracaine gel (4% w/w)
Trial: 14996106
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) gel
Trial: 8315224
Drug: Oral arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral arginine (3 g) plus lysine (3 g) taken twice daily for 14 days
Trial: 8315224
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken twice daily for 14 days
Trial: 3732582
Drug: Cefoxitin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin administered according to a three-dose, 12 h regimen, first injection given immediately after clamping of the umbilical cord.
Trial: 30588573
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (OAC)
Trial: 22060105
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.15 U/kg/die for 18 months)
Trial: 10519166
Drug: Cutaneous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutaneous aspirin (750 mg/day for 10 days)
Trial: 10519166
Drug: Cutaneous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutaneous aspirin
Trial: 1674632
Drug: Propranolol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (6 mg)
Trial: 3885701
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg chlorthalidone
Trial: 7014105
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamide after 100 mg chlorthalidone
Trial: 7014105
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg chlorthalidone after 40 mg xipamide
Trial: 7014105
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamide and 100 mg chlorthalidone
Trial: 31475696
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection of lidocaine in the sphenopalatine ganglion (IL; n=18)
Trial: 31475696
Drug: Endoscopic application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic application of topical lidocaine over sphenopalatine ganglion (TL; n=7)
Trial: 26452230
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy plus electrical stimulation
Trial: 23695232
Drug: Garenoxacin (GRNX)
RxNorm normalized name: garenoxacin
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Garenoxacin (GRNX) 400 mg/day for 4 days
Trial: 23695232
Drug: SBT/ABPC (sulbactam/ampicillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/ABPC (sulbactam/ampicillin) 6 g/day for 3 days followed by continuous administration for 4 days
Trial: 15296473
Drug: CEE/MPA (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate), n=34
Trial: 15296473
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg), n=37
Trial: 15296473
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg), n=40
Trial: 15296473
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no active treatment), n=35
Trial: 10924298
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) and Ticlopidine (2x250 mg/day)
Trial: 10924298
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) and Phenprocoumon (INR 2.0-3.0) with Dipyridamole (3x160 mg/day)
Trial: 1576619
Drug: Lactobacillus vaginal
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus vaginal suppositories
Trial: 1576619
Drug: Sterilized skim-milk
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterilized skim-milk suppositories
Trial: 3691914
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 3% topical minoxidil applied twice daily for 12 months
Trial: 3691914
Drug: 2% topical
RxNorm normalized name: A/T/S 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% topical minoxidil (Regaine) applied twice daily for 1 year
Trial: 31474161
Drug: Intravaginal CO2
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal CO2 laser therapy
Trial: 28741622
Drug: CPP-115 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP-115 (80 mg daily for 6, 10, or 14 days)
Trial: 23275042
Drug: High-dose octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose octreotide (50 μg/h × 3d + 25 μg/h × 4d)
Trial: 23275042
Drug: Low-dose octreotide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose octreotide (25 μg/h × 7d)
Trial: 18606428
Drug: Non-Directly Observed
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Directly Observed Treatment (NDOT)
Trial: 14650364
Drug: Pranlukast 450
RxNorm normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pranlukast 450 mg/day for 1 to 2 years
Trial: 9014622
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at blood concentrations of 1‐10 micrograms ml‐1
Trial: 9014622
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a dose rate of 6.3‐7.8 mg kg‐1 h‐1
Trial: 9014622
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a blood concentration of 2.9 micrograms ml‐1
Trial: 9014622
Drug: Concentration and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration and dose of propofol
Trial: 1563214
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg t.i.d. racemic (R,S)-propranolol
Trial: 1563214
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg t.i.d. optically pure (S)-propranolol
Trial: 22917599
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention consisting of manual tooth/gum brushing, 0.12% chlorhexidine oral rinse administered twice daily by nurses, and upright feeding positioning at meals.
Trial: 8885912
Drug: Oral methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methotrexate, 2.5 mg/day for 5 days
Trial: 3927339
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amphetamine sulfate
Trial: 27153927
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hct normalization and exercise training
Trial: 24758417
Drug: KRG root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRG root (3 g)
Trial: 20626209
Drug: Ciclosporin (2.5-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (2.5-4 mg/kg/day)
Trial: 18494959
Drug: Larval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval therapy ('bagged' and 'loose')
Trial: 18494959
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (hydrogel)
Trial: 7796089
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 50 mg/kg intravenous infusion in saline
Trial: 7796089
Drug: Quinine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine plus intravenous saline (Control)
Trial: 2109477
Drug: Methohexital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (100 mg induction, 10 mg.min‐1 maintenance)
Trial: 2109477
Drug: Midazolam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (15 mg induction, 0.1 mg.min‐1 maintenance) + Flumazenil (0.53 mg mean dose)
Trial: 7356888
Drug: Phenelzine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine treatment for 4 weeks
Trial: 7356888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (5 patients after treatment only)
Trial: 31575509
Drug: Pamrevlumab 30
RxNorm normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamrevlumab 30 mg/kg every 3 weeks for 48 weeks (16 infusions)
Trial: 26343698
Drug: PUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA supplementation (1.3 g of PUFA and 10 mg of vitamin E daily for 12 weeks)
Trial: 26343698
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (11 mg of vitamin E daily for 12 weeks)
Trial: 16340949
Drug: Oligofructose (OFS)
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (OFS) 8 g twice daily (16 g/day)
Trial: 16340949
Drug: Placebo (dextrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrine maltose (DM)) 8 g twice daily (16 g/day)
Trial: 11006176
Drug: Cyclical sequential
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical sequential norethisterone (NET)-based HRT with continuous 2 mg oral oestradiol valerate for three cycles
Trial: 11006176
Drug: Trimegestone-based HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimegestone-based HRT regimens (0.05, 0.1, 0.25 and 0.5 mg/day from day 15-28 for six treatment cycles)
Trial: 9248777
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of mirtazapine in the fasting state
Trial: 9248777
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of mirtazapine after a high-fat meal
Trial: 740581
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with oestrogen and progestogen
Trial: 28724186
Drug: 4% topical
RxNorm normalized name: BPO 4% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% topical formulation of InsP6 applied once a day
Trial: 28724186
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (control)
Trial: 28724186
Drug: 4% topical
RxNorm normalized name: BPO 4% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% topical formulation of InsP6
Trial: 17888460
Drug: GABA‐A/benzodiazepine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA‐A/benzodiazepine receptor inverse agonist selective for the alpha5 subtype (a5IA)
Trial: 11771983
Drug: Scopolamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.3 mg, i.v.)
Trial: 11771983
Drug: Glycopyrrolate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.2 mg, i.v.)
Trial: 8385525
Drug: Lisinopril 10mg
RxNorm normalized name: LISINOPRIL 10MG TAB
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril 10mg once daily
Trial: 8385525
Drug: Enalapril 10mg
RxNorm normalized name: enalapril 10 MG
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 10mg once daily
Trial: 25231730
Drug: High-Ca group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Ca group (actual Ca intake: 1243 mg/d)
Trial: 25231730
Drug: Medium-Ca group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-Ca group (actual Ca intake: 985 mg/d)
Trial: 27980462
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg QD
Trial: 22664798
Drug: Edoxaban 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 45 mg QD
Trial: 22664798
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg QD
Trial: 19520690
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab plus PDT using a light dose of 25 J/cm2 (group 1)
Trial: 19520690
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab plus PDT using a light dose of 12 J/cm2 (group 2)
Trial: 14963719
Drug: Betamethasone solution
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone solution (0.4 mg/ml)
Trial: 7271298
Drug: Chemotherapy (2-year
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (2-year course)
Trial: 23435159
Drug: Basal-bolus regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus regimen with glargine once daily and glulisine before meals
Trial: 26459273
Drug: Premixed human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed human insulin (30% regular insulin and 70% NPH insulin) twice daily
Trial: 26459273
Drug: Premixed human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed human insulin
Trial: 21795430
Drug: Calcium doses
RxNorm normalized name: Docusate Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium doses ≥1000 mg
Trial: 21795430
Drug: Calcium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dose of 800 mg
Trial: 2498565
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of propranolol (4 or 3 times daily)
Trial: 2498565
Drug: Intermittent regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent regimen of propranolol (twice daily)
Trial: 2498565
Drug: Twice-daily regimen
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily regimen of propranolol
Trial: 2498565
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily doses of propranolol
Trial: 27930613
Drug: Community empowerment-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community empowerment-based combination HIV prevention model (Project Shikamana)
Trial: 26231305
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg administered monthly
Trial: 26231305
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg administered as needed (PRN) after 3 monthly loading doses
Trial: 24597260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without any analgesic measurements
Trial: 21406193
Drug: Ubiquinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (100 mg/day)
Trial: 21406193
Drug: Ubiquinone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinone (100 mg/day)
Trial: 14662586
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with ablation of the avascular retina
Trial: 14662586
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (control eye)
Trial: 10960936
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy (physical therapy and occupational therapy)
Trial: 1467105
Drug: Closed-loop computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop computer control of an infusion of a 5:1 mixture of trimetaphan camsylate (TMP) and sodium nitroprusside (SNP)
Trial: 6086866
Drug: VZIG (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VZIG (standard doses)
Trial: 6086866
Drug: IGIV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV at 4 ml/kg every 4 weeks for four doses
Trial: 6086866
Drug: IGIV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV at 6 ml/kg every 6 weeks for two to four doses
Trial: 6086866
Drug: IGIV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV at 4 ml/kg
Trial: 6086866
Drug: IGIV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV at 6 ml/kg
Trial: 30922731
Drug: Lenvatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib plus pembrolizumab (20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks)
Trial: 26488145
Drug: Arthrocentesis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis group (aspiration before hyaluronan injection)
Trial: 26488145
Drug: Nonarthrocentesis group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonarthrocentesis group (no aspiration before hyaluronan injection)
Trial: 20362976
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) based on exposure and mindfulness exercises delivered via the Internet.
Trial: 18847622
Drug: School nurse
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School nurse supervision of glucose and insulin-dose adjustment (3-month intervention)
Trial: 16212578
Drug: sub-antimicrobial doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sub-antimicrobial doxycycline (20 mg, bid)
Trial: 11840077
Drug: Standard titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titer (50% tissue culture‐infective dose, 103.8) Schwarz measles vaccine after meningococcal vaccine
Trial: 11840077
Drug: Increased titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased titer (10(4.7) PFU) Edmonston‐Zagreb measles vaccine followed by meningococcal vaccine
Trial: 11840077
Drug: Increased titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased titer (10(4.7) PFU) Connaught vaccine followed by standard titer Schwarz measles vaccine
Trial: 1981019
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg alone
Trial: 1981019
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg with rifampicin 600 mg once daily
Trial: 1981019
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg with ranitidine 150 mg twice daily
Trial: 31185906
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral paracetamol